# Click Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/click-therapeutics

- Industry: Software
- Headquarters: New York, US
- Website: www.clicktherapeutics.com
- Total disclosed funding: $120M
- Latest round: Series D (Apr 9, 2026)
- Investors on record: 10

## About

Based in the US, Click Therapeutics, Inc. develops innovative digital therapeutics that combine neuroscience and advanced software to improve patient health outcomes across various mental and physical conditions. Click Therapeutics, Inc. specializes in creating prescription digital therapeutics that serve as adjuncts to traditional pharmacotherapy. Founded in 2012, the company is headquartered in New York, US. The founders, Bruce Leuchter, David Klein, Michael McAllister, and Wei Zhou, have extensive backgrounds in the health tech industry. Click Therapeutics focuses on patient-centric digital treatments, prominently featuring Click SE™ solutions, which are prescription digital therapeutics aimed at enhancing traditional pharmacotherapy. These solutions address unmet clinical needs in areas such as mental health and migraines, ensuring clinical validation through rigorous trials. The company primarily serves healthcare providers and patients in the US and select international markets.Click Therapeutics operates a revenue model centered on the commercialization of their prescription digital therapeutics, including Click SE™ solutions. These digital treatments are typically prescribed through partnerships with healthcare providers, utilizing a subscription-based pricing structure. This model enables seamless integration of digital health solutions into patient care plans, fostering sustainable revenue by aligning financial interests with improved patient outcomes. David Klein serves as the CEO of the company. In April 2026, Click Therapeutics, Inc. raised USD 50 million in series D funding from Boehringer Ingelheim Venture. The company plans to use the April 2026 funding to take over and support the commercialization of CT-155, including bringing the prescription digital therapeutic for schizophrenia through regulatory clearance and launch.

## Funding rounds

- Series D, Apr 9, 2026, $50M — Boehringer Ingelheim Venture
- Series B, Oct 22, 2021, $52M — H.I.G. BioHealth Partners, Sanofi Ventures, Accelmed, Revelation Partners, Health Catalyst Capital Management, Hikma Ventures, Ridgetop Capital Partners, K2 HealthVentures
- Series A, Jun 15, 2018, $17M — Sanofi Ventures
- Seed, Apr 15, 2012, $0.2M — Supernode Ventures

## Investors

- Supernode Ventures (https://capitalatlas.ai/funds/supernode-ventures) — Seed
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A, Series B
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series B
- Accelmed (https://capitalatlas.ai/funds/accelmed) — Series B
- Revelation Partners (https://capitalatlas.ai/funds/revelation-partners) — Series B
- Health Catalyst Capital Management (https://capitalatlas.ai/funds/health-catalyst-capital-management) — Series B
- Hikma Ventures (https://capitalatlas.ai/funds/hikma-ventures) — Series B
- Ridgetop Capital Partners (https://capitalatlas.ai/funds/ridgetop-capital-partners) — Series B
- K2 HealthVentures (https://capitalatlas.ai/funds/k2-healthventures) — Series B
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series D